论文部分内容阅读
目的探讨骨髓增生异常综合征(MDS)患者骨髓CD117的表达及意义。方法采用直接免疫荧光标记法标记细胞表面分化抗原,经流式细胞术测定,对31例MDS患者骨髓的CD117表达及意义进行分析。依据MDS的WHO分型方案、染色体核型以及国际预后积分系统(IPSS)将MDS患者划分为RA/RARS/RCMD组、RAEBⅠ/RAEBⅡ组;染色体良好组、染色体不良组;中危Ⅰ组、中危Ⅱ组、高危组。结果(1)RAEBⅠ/RAEBⅡ组CD117表达阳性率及表达荧光强度均较RA/RARS/RCMD组高(P<0.01);(2)染色体不良组CD117表达阳性率明显高于染色体良好组(P<0.05);(3)CD117在高危组、中危Ⅱ组的表达阳性率较中危Ⅰ组高(P<0.05),且CD117在高危组、中危Ⅰ组,中危Ⅱ组与中危Ⅰ组间的表达差异亦有显著统计学意义(P均<0.01)。结论CD117检测有助于MDS的分型及预后判断。
Objective To investigate the expression and significance of bone marrow CD117 in patients with myelodysplastic syndrome (MDS). Methods Direct immunofluorescence labeling was used to label cell surface differentiation antigen. The expression of CD117 in bone marrow of 31 MDS patients and its significance were analyzed by flow cytometry. The patients with MDS were divided into RA / RARS / RCMD group and RAEBⅠ / RAEBⅡ group according to the WHO classification scheme of MDS, chromosome karyotype and International Prognostic Score System (IPSS). Chromosome well group and chromosomal poor group; Dan Ⅱ group, high-risk group. Results (1) The positive rate and the expression of CD117 in RAEBⅠ / RAEBⅡgroup were higher than those in RA / RARS / RCMD group (P <0.01). (2) The positive rate of CD117 in RAEB Ⅰ / RAEBⅡgroup was significantly higher than that in the healthy group (P < 0.05). (3) The positive expression rate of CD117 in high risk group and intermediate risk group Ⅱ was higher than that in intermediate risk group Ⅰ (P <0.05), and the positive rate of CD117 in high risk group, intermediate risk group Ⅰ, There were also significant differences in the expression between groups (all P <0.01). Conclusion The detection of CD117 contributes to the classification and prognosis of MDS.